Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/511,657
Filing Date	April 18, 2005
First Named Inventor	Drumm
Group Art Unit	1635
Examiner Name	Wollenberger, Louis V.
Attorney Docket Number	129402.00201

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/L.W./	A1	2002/0054902	A1	Pardridge	05-09-2002		
	A2	5,550,289	A	Eppstein et al.	08-27-1996		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			T
	B1	WO	98/48009	A2	University of Florida	10-29-1998				
	B2	WO	94/08026	A1	Rhone-Poulenc Rorer S.A.	04-14-1994				
	B3	WO	02/11666	A2	D-Pharm Ltd.	02-14-2002				
	B4	WO	99/12572	A1	University of Florida	03-18-1999				
	B5	EP	1229134	A2	Necleonics, Inc. et al.	08-07-2002				
	B6	WO	01/83729	A	Novartis AG	11-08-2001				
	B7	WO	01/36646	A	Cancer Res. Campaign Tech Lim	05-25-2001				
	B8	WO	00/44914	A	Medical College of Georgia Research Institute	08-03-2000				
	B9	WO	02/088320	A	University of Florida	11-07-2002				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T
	C1	CARLSON et al., Perineurium in the Drosophila embryo and its role in the blood-brain/nerve barrier, 1998, Int. J. Insect Morphology and Embryology 27(2):61-66	
	C2	BANKS et al., Delivery across the blood-brain barrier of antisense directed against Amyloid beta: reversal of learning and memory deficits in mice overexpressing Amyloid precursor protein, 2001, J. Pharmacology and Experimental Therapeutics 297(3):1113-1121	
	C3	PARDRIDGE et al., Vector-mediated delivery of a polymamide ("peptide") mucleic acid analogue through the blood-brain barrier in vivo, 1995, Proc. Nat. Acad. Sci. USA 92:5592-5596	
	C4	BOADO et al., Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS, 1998, J. Pharm. Sci. 87(11):1308-1315	
	C5	TYLER et al., Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression, 1999, Proc. Natl. Acad. Sci. USA 96:7053-7058	
	C6	LEE et al., Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology, 2002, J. Nuclear Medicine 43(7):948-956	
	C7	PENICHET et al., An antibody-Avidin fusion protein specific for the Transferrin Receptor serves as a delivery vehicle for the effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain, 1999, J. Immun. 163:4421-4426	
	C8	WU et al., Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeaoxynucleotide conjugated to a vector-mediated drug delivery system, 1996, J. Pharm. Exp. Ther. and Am. Soc. Pharm. 276(1):206-211	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

PATENT

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (use as many sheets as necessary)				**Complete if Known**	
				Application Number	10/511,657
				Filing Date	April 18, 2005
				First Named Inventor	Drumm
				Group Art Unit	1635
				Examiner Name	Wollenberger, Louis V
Sheet	2	of	2	Attorney Docket Number	129402.00201

/L.W./	C9	SHI et al., Antisense imaging of gene expression in the brain in vivo, 2000, Proc. Natl. Acad. Sci. USA 97(26):14709-14714	
	C10	BOADO, Antisense drug delivery through the blood-brain barrier, 1995, Adv. Drug Delivery Reviews 15(1/3):73-107	
	C11	PINEDA et al., The genetic network of prototypic planarian eye regeneration is Pax6 independent, 2002, Development 129:1423-1434	
	C12	DRYJA et al., Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa, 1995, Proc. Natl. Acad. Sci. USA 92:10177-10181	
	C13	HUNT et al., Vitreous treatment of retinal pigment epithelial cells results in decreased expression of FGF-2, 1998, Investigative Ophthalmology & Visual Sci. 39(11):2111-2120	
	C14	KOCIOK et al., Vitreous treatment of cultured human RPE cells results in differential expression of 10 new genes, 2002, Investigative Ophthalmology & Visual Sci. 43(7):2474-2480	
	C15	CAMPOCHIARO, Gene therapy for retinal and choroidal diseases, 2002, Expert Opinion on Biological Therapy, 2(5):537-544	
	C16	KOCIOK et al., Upregulation of RAS-GTPase Activating Protein (GAP)-Binding Protein (G38BP) in proliferating RPE cells, 1999, J. Cellular Biochemistry 74:194-201	
	C17	CHAN et al., Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma, 2003, Ophthalmology 110(2):421-426	
	C18	AVGEROPOULOS et al., New treatment strategies for malignant gliomas, 1999, The Oncologist 4:209-224	
	C19	GROOTHUIS, The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery, 2000, Neuro-Oncology 2:45-59	
	C20	PARDRIDGE, Brain drug targeting and gene technologies, 2001, Japanese J. Pharmacology 87:97-103	
	C21	PARDRIEGE, Drug and gene targeting to the brain with molecular Trojan horses, 2002, Nature Reviews 1:131-139	
	C22	QIAN et al., Targeted drug delivery via the Transferrin Receptor mediated endocytosis pathway, 2002, Pharmacological Reviews 54(4):561-587	
	C23	PARDRIDGE, Vector-Mediated drug delivery to the brain, 1999, Advanced Drug Delivery Reviews, 36(2-3):299-321	
	C24	PARDRIDGE, CNS drug design based onprinciples of blood-brain barrier transport, 1998, J. Neurochemistry 70:1781-1792	
	C25	PARDRIDGE, Drug delivery to the brain, 1997, J. Cerebral Blood Flow and Metabolism, 17(7):713-731	
	C26	PHILIP et al., Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells, 2003, Investigative Ophthalmology & Visual Sci. 44(4):1716-1721	

Examiner Signature	/Louis Wollenberger/	Date Considered	01/14/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.